1. Scrip

Device Financings: Recent Growth, Future Opportunities

A Reprint--see the article of the same name in In Vivo, May 2008.

Deanna Deinzer and Maureen Riordan, Windhover deals analysts, assisted with the preparation of the charts and data for this article.

The last several years have marked an exciting revival of investor interest in the medical device sector. This renaissance has...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

BIO China Deal Perspectives: A Dramatic Impact On Industry’s R&D Pipelines

 
• By Mandy Jackson

Biopharma executives and investors at the BIO convention noted the competition emerging from China with high-quality assets that could make strong additions to their portfolios.

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Removal Of REMS For CAR-Ts Could Greatly Expand Their Reach

 
• By Alaric DeArment

The FDA eliminated REMS requirements for approved CAR-T cell therapies that have limited their availability, a move that could enable increased use in the community setting.